GlassScriptPhysician profile
Sean M Macdermott
NPI 1326085432
$1,820.93
in general payments reported to CMS, 2019-2025
17 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $556 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $416.04 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $373.88 | 2024-2025 | Nucala, Shingrix, Arexvy |
| Regeneron Healthcare Solutions, INC. | $188.32 | 2024-2025 | Dupixent |
| Genzyme Corporation | $152.71 | 2024-2025 | |
| Verona Pharma, INC. | $136.64 | 2025 | Ohtuvayre |
| Insmed, INC. | $82.13 | 2024-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $79.94 | 2024-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $74.24 | 2024-2025 | Tezspire |
| Viatris Specialty LLC | $73.12 | 2025 | Yupelri |
| Electromed, INC. | $49.04 | 2024-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $36.99 | 2024 | Acthar |
| Actelion Pharmaceuticals US, INC. | $33.00 | 2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $31.66 | 2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $28.50 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.72 | 2024 | Ofev |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $21.91 | 2024 | Yupelri |
| Phadia US INC. | $18.09 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Macdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.